

In such a delicate moment for public health, **Wiva Group** actively engages by offering its contribution in the elimination of viral and flu strains through its **Wivactive system**.

After having invested more than 3 million euros and 7 years of research, the technical committee of **Wiva Group** assisted by that of Ce.Ri.Col. (Internationally renowned scientific partner) has decided to invest another 200 thousand euros to implement the tests in this specific direction.

In the middle of February 2020, **Wiva Group** commissioned the International Eurofin Biolab Laboratory to ensured and certify the antibacterial action by checking it on one of the most important harmful bacteria of normal circulation as Escherichia Coli K12.

The same procedure has been focused also for the anti-allergen action by reducing the mite (acarus) proteins.

Finally, in the last period, antiviral research has been intensified, focusing particularly on groups belonging to the "Coronavirus". This activity was supported by important findings obtained through the doped titanium dioxide used by the **Wivactive system**.

**Wiva Group** is aware that the path taken will not be so easy to follow but is confident of achieving important results at the end of the related scientific checks.

Always careful and keen to the research and development of high-tech products, **Wiva Group** is at the forefront in creating solutions for the well-being and health of the community.

For further information and information:

wivactive@wivagroup.com





